SLS stock has skyrocketed more than 200%, putting SELLAS Life Sciences among the market’s biggest gainers after a major breakthrough in its Phase 3 cancer vaccine trial. The sharp rally followed results showing a 41% reduction in the risk of death among patients with acute myeloid leukemia, giving the company a potentially significant path toward …
Source link







